Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
about
Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease managementMitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosisNeuromyelitis optica: clinical features, immunopathogenesis and treatment.Chemotherapeutics in the treatment of multiple sclerosis.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disabilityAn integrated approach to design novel therapeutic interventions for demyelinating disordersThe effect of omega-3 fatty acids on central nervous system remyelination in fat-1 miceEpigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.A critical appraisal of treatment decisions in multiple sclerosis--old versus new.Pharmacogenomics in neurology: current state and future steps.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.The transition from first-line to second-line therapy in multiple sclerosis.Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.[Therapeutic options for autoimmune encephalomyelitis].Drugs approved for the treatment of multiple sclerosis: review of their safety profile.[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].[Current immunotherapy of multiple sclerosis].Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
P2860
Q26796643-0394B26B-6019-40DF-A600-CB0967A6F69AQ28480940-B0C0CCAC-922C-4AD5-8C5F-7B8400F85676Q30785267-82A11091-4FDB-4F08-99B5-A44CEE2419B5Q34409536-132DAE39-DD4D-4E2D-834E-A4A29E3D4569Q35052199-4C553650-EF1D-46C7-AA8B-40D2E45D6190Q35866381-1B9F1D93-DF26-4086-9F1A-007E90CEBABCQ36059972-8735D248-C4DE-4508-99FC-FB8EE19ACB94Q36257833-4BE6C05A-DEAE-46F6-A4CD-ABFA94FEC65EQ36648907-D71D0A4B-3A11-441E-A7A2-1875F55BE26BQ37615119-4260BF43-9F43-4322-BCBB-32BB24019204Q37862062-4F1267B2-1EE7-4813-8C3A-23BB2D1B4765Q37967607-97C483C8-0B38-4C18-924F-67E6C94C8322Q38172961-1E7C8B3A-A4B6-49A0-9A51-02EA15FD03A4Q41014662-D056B6D9-1CB9-46B6-B943-D3F6146F075EQ41096503-0080242C-ACE9-4134-9BF6-F5EF457427B5Q41998267-D9D62067-BD22-4522-B209-87DB5D642E1AQ43607388-F30D4B1F-E146-4A10-8EB6-F60CB3B44356Q47868767-B3FF4C48-3351-4E17-AB18-1353B6852B75Q52855510-482A7FF3-87CC-4D32-9B88-502D884D6F6EQ52863422-F5423FFE-7E53-4ABA-BF0F-5D56DD736B6AQ58573155-2EA2EB60-0499-497C-A66F-4DA3B32A79EE
P2860
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Severe cardiac failure in a pa ...... w-dose mitoxantrone treatment.
@en
type
label
Severe cardiac failure in a pa ...... w-dose mitoxantrone treatment.
@en
prefLabel
Severe cardiac failure in a pa ...... w-dose mitoxantrone treatment.
@en
P2093
P1433
P1476
Severe cardiac failure in a pa ...... w-dose mitoxantrone treatment.
@en
P2093
K J G Schmailzl
N von Ahsen
P304
P356
10.1212/WNL.0B013E3181B878F6
P407
P577
2009-09-01T00:00:00Z